Latest / The Macro Memo with Fexingo: Daily Conversations on Inflation, GDP, and Federal Reserve Policy / How Generic Drug Tariffs Could Reshape Inflation
Transcript
- Lucas: So import prices from China just hit their highest level since 2008. That's a big number, and it's got people asking whether we're about to see a broader shift in trade costs. Luna: Right, and that ties into something else that crossed the wire this week — the Trump administration announced plans to impose tariffs on generic drugs starting in 2028, with a two-year delay built in. Lucas: Exactly. That's the angle I want to dig into. Because generic drugs are this quiet behemoth in the CPI basket. They're about 1.5 percent of the overall index, but for millions of households, they're a daily cost. And right now, those drugs are almost entirely imported. Luna: So the question is, can you onshore something like that in two years? And what happens to prices in the meantime? Lucas: Right. Let's start with the basics. The vast majority of active pharmaceutical ingredients — APIs — come from China and India. For some common generics like amoxicillin or metformin, the share is over 80 percent. So if you slap a tariff on those imports, the cost doesn't just disappear. Luna: And the two-year delay is ostensibly to give domestic manufacturers time to ramp up. But building a pharmaceutical plant isn't like opening a warehouse. You need FDA approvals, quality controls, supply chain logistics. Lucas: Exactly. The Congressional Budget Office actually looked at something similar a few years ago and estimated that even with accelerated approvals, it takes at least three to five years to bring a new generic drug manufacturing facility online. So the two-year window feels optimistic. Luna: Which means during that period, you might not see much onshoring, but you could see price increases as importers pass on the tariff cost. Lucas: That's the key mechanism. The tariff would be applied at the border, so the cost gets added to the wholesale price. And because generic drugs are a commodity-like market with thin margins, those cost increases are likely to be passed through quickly. Luna: And that feeds into the inflation data we're already watching. Core PCE is still running at about 2.6 percent — above the Fed's target. The last thing they want is a new source of upward pressure. Lucas: Right. And remember, the Fed is in a delicate spot. The effective fed funds rate is at 3.63 percent, and they've been signaling cuts later this year. But if a tariff-driven spike in drug costs shows up in the data, that could complicate things. Luna: It's also worth noting that this isn't just about inflation. There's a national security angle too. During COVID, we saw shortages of critical generic drugs because the supply chain was concentrated overseas. Lucas: Absolutely. The pandemic exposed how fragile that supply chain is. So onshoring has a resilience argument. But the question is whether tariffs are the right tool. Some economists argue that direct subsidies or tax credits for domestic production would be more efficient. Luna: Tariffs are a blunt instrument. They raise costs for everyone, and they can lead to retaliation. China already has a history of targeting US agricultural exports when trade tensions escalate. Lucas: And that's the broader context here. Import prices from China are already elevated. If you layer on another tariff on a critical category like drugs, you risk a broader trade conflict. Luna: So let's talk about what this might mean for the average person. Generic drugs are cheap — that's their whole value proposition. A month's supply of a common blood pressure medication might cost $4. If tariffs add even 10 percent, that's not huge in absolute terms, but for people on multiple medications, it adds up. Lucas: And for the healthcare system overall, it's significant. Medicare and Medicaid are huge purchasers of generics. Higher drug costs mean higher government spending, which affects the fiscal picture. Luna: Right. So you've got this intersection of trade policy, inflation, healthcare, and fiscal policy. It's a lot of moving parts. Lucas: And that's why this is such a fascinating episode. We're looking at a policy that won't even take effect for two years, but the signals are already being priced into supply chains. Luna: You know, something like this also makes me think about how we fund the show. It's a similar kind of commitment — building something sustainable that doesn't rely on flashy ads or corporate backing. Lucas: Yeah, it's a good parallel. We keep The Macro Memo ad-free and independent because a small group of listeners chips in monthly through buy me a coffee dot com slash fexingo. That's literally what covers the research and production. Luna: Exactly. It's not a huge number, but it's enough to keep us going. And it means we can talk about tariffs or Fed policy without worrying about sponsors. Lucas: Right. So if walking through the economy with us has made something click, consider joining that group. It's buy me a coffee dot com slash fexingo. Now, back to the tariff question. Luna: So, back to the two-year timeline. Is there any historical precedent for a successful onshoring push that fast? Lucas: Not really. Look at semiconductors. The CHIPS Act was passed in 2022, and we're still years away from meaningful domestic output. Pharma is even more regulated. Luna: So the delay might be more about politics than economics. Give the administration time to claim progress while avoiding immediate price spikes. Lucas: That's a cynical take, but probably accurate. And in the meantime, the Fed has to navigate this uncertainty. The 10-year breakeven inflation rate is at 2.28 percent — up slightly from last month. That suggests markets see some inflation risk ahead. Luna: And the yield curve is steepening. The 10-year Treasury is at 4.70 percent, the 2-year at 3.80 percent. That's a 90-basis-point spread, which is pretty wide. Lucas: Yeah, that's a signal that bond markets expect growth and inflation to pick up. So if drug tariffs add to that, the Fed might have to hold off on cuts longer than they'd like. Luna: But on the other hand, the jobs market is cooling. Unemployment dropped to 4.2 percent, but initial jobless claims just fell sharply to 187,000 — that's low. So it's mixed signals. Lucas: Exactly. The Fed is data-dependent, and the data is contradictory. That's why we're having this conversation — to parse what matters. Luna: So the key takeaway: generic drug tariffs are on the table, but the impact won't be felt until 2028 at the earliest. In the meantime, we watch import prices, supply chain moves, and any legislative changes. Lucas: And we keep an eye on that core PCE number. If it starts climbing again, this tariff plan will be a factor. For now, it's a policy in waiting.